Study summary · research use only
Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this mouse study of acute kidney injury (AKI), researchers designed a self-assembling GHRP-6 peptide hydrogel and tested whether it could alter metabolism in renal tubular epithelial cells (TECs) to aid recovery. Metabolomic sequencing of AKI mice treated with the GHRP-6 hydrogel showed high enrichment of spermidine, L-glutamine, and acetyl-CoA, metabolites involved in amino acid and fatty acid metabolism. Further experiments indicated that GHRP-6 hydrogel treatment increased survival of TECs in the ischemic microenvironment by activating the mTOR-P70 pathway. The authors describe the GHRP-6 hydrogel as acting through metabolic reprogramming of TECs in this AKI model, proposing it as a candidate strategy for protecting TECs during AKI.
Abstract
Renal tubular epithelial cells (TECs), which are highly susceptible to injury during acute kidney injury (AKI), have notable regenerative effects on renal recovery after AKI. AKI-driven metabolic reprogramming of TECs plays a critical role in determining whether kidneys recover functionally or develop fibrosis. Targeting the metabolism of TECs offers valuable insights into AKI treatment. Growth hormone-releasing hormone (GHRH) and its analog GHRH peptide (GHRP) play beneficial roles in the field of regenerative medicine. Here, we designed a self-assembling GHRP-6 peptide hydrogel, and we hypothesized that this hydrogel could reprogram the metabolism of TECs, further enhancing recovery from AKI. Metabolomic sequencing analysis revealed that spermidine, L-glutamine, and acetyl-CoA, which are involved in amino acid and fatty acid metabolism, were highly enriched in a mouse model of AKI treated with the GHRP-6 hydrogel. Further study revealed that GHRP-6 hydrogel treatment enhanced the survival of TECs in the ischemic microenvironment by activating the mTOR-P70 pathway. In conclusion, GHRP-6 hydrogel treatment has beneficial therapeutic effects on AKI through the targeting of metabolic reprogramming, which offers a novel therapeutic strategy to protect TECs in AKI treatment.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.